Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

2.0%

1 terminated/withdrawn out of 51 trials

Success Rate

98.0%

+11.5% vs industry average

Late-Stage Pipeline

55%

28 trials in Phase 3/4

Results Transparency

15%

7 of 48 completed trials have results

Key Signals

7 with results

Enrollment Performance

Analytics

Phase 3
21(42.0%)
Phase 1
7(14.0%)
Phase 2
7(14.0%)
N/A
7(14.0%)
Phase 4
7(14.0%)
Early Phase 1
1(2.0%)
50Total
Phase 3(21)
Phase 1(7)
Phase 2(7)
N/A(7)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (51)

Showing 20 of 51 trials
NCT04157686Phase 3Completed

MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)

Role: lead

NCT01485601Phase 2Completed

Safety and Efficacy Study of Botulinum Toxin Type A to Treat Glabellar Lines

Role: lead

NCT03785145Phase 3Completed

MT10109L in the Treatment of Lateral Canthal Lines

Role: lead

NCT03795922Phase 3Completed

MT10109L in the Treatment of Glabellar Lines

Role: lead

NCT03732833Phase 3Completed

MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines

Role: lead

NCT03721016Phase 3Completed

MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)

Role: lead

NCT05195112Phase 3Completed

Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat

Role: lead

NCT05164003Phase 1Completed

CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase1)

Role: lead

NCT03289702Phase 3Completed

CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase3)

Role: lead

NCT04143815Phase 2Completed

Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines

Role: lead

NCT03754413Not ApplicableCompleted

Neuramis® Volume Lidocaine for Volume Augmentation in the Mid-Face

Role: lead

NCT04143854Phase 2Completed

Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Lateral Canthal Lines

Role: lead

NCT02721368Not ApplicableCompleted

Neuramis® Volume Lidocaine Treatment in Patients With Loss of Mid-face Volume

Role: lead

NCT03289169Phase 4Completed

Long-term Safety and Efficacy of MEDITOXIN® in Treatment Glabellar Lines

Role: lead

NCT03796351Phase 1Completed

Pharmacodynamic and Safety of MT10107(Botulinum Type A Neurotoxin) in Comparison to BOTOX®

Role: lead

NCT04007211Not ApplicableCompleted

Pivotal Clinical Study to Assess the Anti-adhesive Effect and Safety of ABT13107 Applied to Postoperative Intrauterine

Role: lead

NCT03905291Phase 1Completed

Pharmacokinetic/Pharmacodynamic Characteristics and Safety/Tolerability of MT921 in Healthy Subjects

Role: lead

NCT04496427Completed

Observational Study to Determine the Efficacy and Safety of Potenfill for Temporary Penile Enhancement

Role: lead

NCT04144049Phase 2Completed

A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat

Role: lead

NCT03837561Phase 3Completed

The Efficacy and Safety of CUNOX® in Patients With Moderate to Severe Glabellar Lines

Role: lead